高危型HPV在前列腺腺癌中的表达及临床意义

Expression and clinical significance of high-risk HPV in prostate adenocarcinoma

目的探讨高危型HPV在前列腺腺癌组织中的表达情况.方法选取50例前列腺腺癌组织标本(Pca组)和52例前列腺增生组织(BPH组),通过聚合酶链式反应(PCR)结合反向点杂交(RDB)技术检测17种高危型HPV(16、18、31、33、35、39、45、51、52、53、56、58、59、68、73、83、MM4)的表达情况.结果 50例前列腺癌患者中17例患者存在高危型HPV阳性表达,52例前列腺增生患者中4例存在高危型HPV阳性表达,差异有统计学意义(x2=10.29,P=0.001).HPV16的阳性表达率最高,前列腺癌组阳性表达11例(22.0%),前列腺增生组中阳性表达3例(5.7%),两组比较有统计学差异(x2=5.671,P=0.017);HPV18阳性表达率次之,前列腺癌组阳性表达9例(18.0%),前列腺增生组中阳性表达2例(3.8%),两组比较有统计学差异(x2=5.307,P=0.021).结论高危型HPV在前列腺腺癌和前列腺增生组织中的表达具有一定的差异,一定程度上提示高危型HPV感染与前列腺癌的发生发展可能存在一定的关系.

Objective To investigate the expression of high-risk HPV in prostate adenocarcinoma. Methods A total of 50 specimens of prostate adenocarcinoma(Pca group) and 52 specimens of benign prostatic hyperplasia(BPH group) were selected. Polymerase chain reaction (PCR) combined with reverse dot blot (RDB) technique was used to detect the expressions of 17 high-risk HPVs(16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 68, 73, 83, MM4). Results Among the 50 patients with prostate cancer, 17 patients had high-risk HPV positive expression, and 4 cases of 52 patients with benign prostatic hyperplasia had high-risk HPV positive expression, and the difference was statistically significant (χ2=10.29, P=0.001). The positive expression rate of HPV16 was the highest, with 11 cases(22.0%) of positive expression in prostate cancer group and 3 cases(5.7%) of positive expression in prostatic hyperplasia group. There was significant difference between the two groups (χ2=5.671, P=0.017). The positive expression rate of HPV18 followed, with 9 cases(18.0%) of positive expression in prostate cancer group and 2 cases(3.8%) of positive expression in prostatic hyperplasia group. There was significant difference between the two groups(χ2=5.307, P=0.021). Conclusion The expression of high-risk HPV in prostate adenocarcinoma and benign prostatic hyperplasia has certain differences. To some extent, there may be a certain relationship between high-risk HPV infection and the development of prostate cancer.